Skip to content

Psychedelic-assisted therapy: all studies

Page 218 of 294: studies 2,171 to 2,180 of 2,939, newest first. Back to the psychedelic-assisted therapy overview

Research

Psychoplastogens: A Novel Therapeutic Approach for Neurological Diseases and Disorders.

ACS Medicinal Chemistry Letters September 14, 2023 Robert B. Kargbo 3 citations

Neurological diseases often involve changes in synaptic connectivity and plasticity. Psychoplastogens, substances that stimulate neuronal growth and enhance neural structures, show promise in mitigating these changes. They activate key biological targets, including AMPA receptors, TrkB, and mTOR. Substances like ketamine, scopolamine, N,N-dimethyltryptamine, and rapastinel have...

Psychedelic Commercialization: A Wide-Spanning Overview of the Emerging Psychedelic Industry.

Psychedelic Medicine September 13, 2023 Jacob S. Aday, Brian S. Barnett, Dan Grossman et al. 56 citations

Background: In the wake of positive clinical trial outcomes of psychedelic-assisted psychotherapy for the treatment of various psychiatric disorders, there has been an influx of financial investment into psychedelic drug development from the pharmaceutical and biotech sectors. Psychedelics are now a multibillion dollar industry, with hundreds of companies that are seeking to commercialize...

DOI: 10.1089/psymed.2023.0013 (opens in new tab) Full text (opens in new tab) Psychedelics Pharmaceutical-industry Mental-health-treatment Indigenous-medicine +1

The Use of Illicit Drugs in Therapy: an Introduction

Current Addiction Reports September 8, 2023 Anna Ross, Jake Hawthorn

Abstract Purpose of Review The use of certain illicit substances as a form of therapy, and particularly as an adjunct to psychotherapy, has gained increasing media and academic attention over the last decade, culminating in what has been coined “the psychedelic renaissance.” This section in Current Addiction Reports has been developed in order to highlight the new and emerging research around...

Molecular and structural insights into the 5‐HT2C receptor as a therapeutic target for substance use disorders

British Journal of Pharmacology September 8, 2023 Maleesha Ubhayarathna, Christopher J. Langmead, Natalie Diepenhorst et al. 10 citations

Abstract Substance use disorder (SUD) is a chronic condition, with maintained abuse of a substance leading to physiological and psychological alterations and often changes in cognitive and social behaviours. Current therapies include psychotherapy coupled with medication; however, high relapse rates reveal the shortcomings of these therapies. The signalling, expression profile, and neurological...

DOI: 10.1111/bph.16233 (opens in new tab) Serotonin Context archaeology 5-ht2c receptor Functional selectivity +4

Evolving antidepressant: from SSRIs to psychedelic

International Conference on Modern Medicine and Global Health September 7, 2023 H. Hong

SSRIs mediate antidepressant effects by inhibiting specific serotonin transport(SERT) and subsequent modulation of serotonin levels in the brain. This review paper provides an overview of the mechanisms of action of selective serotonin reuptake inhibitors (SSRIs), as well as psychedelics, including their potential therapeutic applications in treating psychiatric disorders. By examining the...

Cultural Biases and Psychedelic Experiences: Western Scientific Perspectives about Amazonian Mestizo Therapeutic Traditions

OBM Integrative and Complementary Medicine September 7, 2023 Alberto Dubbini

This article aims to analyze how Western researchers can be influenced by their epistemic and ethical foundations, which are also expressed through a culturally shared idea of therapy, and how this influence can significantly hinder the understanding of a different cultural reality and its resources in terms of knowledge and practices. While examining a collection of research cases in the field...

DOI: 10.21926/obm.icm.2303035 (opens in new tab) Full text (opens in new tab) Context archaeology Epistemology Relevance law Value mathematics

Open-label study of consecutive ibogaine and 5-MeO-DMT assisted-therapy for trauma-exposed male Special Operations Forces Veterans: prospective data from a clinical program in Mexico.

The American Journal of Drug and Alcohol Abuse September 3, 2023 Alan Kooi Davis, Yitong Xin, Nathan D. Sepeda et al. 29 citations

Background: Research in psychedelic medicine has focused primarily on civilian populations. Further study is needed to understand whether these treatments are effective for Veteran populations.Objectives: Here, we examine the effectiveness of psychedelic-assisted therapy among trauma-exposed Special Operations Forces Veterans (SOFV) seeking treatment for cognitive and mental health problems in...

Does acute stress play a role in the lasting therapeutic effects of psychedelic drugs?

Neuropsychopharmacology September 1, 2023 Harriet de Wit, M Heilig, Anya K. Bershad

Psychedelic drugs, when used in the context of psychotherapy, can produce significant and long-lasting memories with enduring beneficial effects. Yet, the behavioral and neurobiological mechanisms that underlie these beneficial effects remain a mystery. Here, we suggest that both the quality and durability of memories of the drug-facilitated therapeutic experience may be mediated, in part, by...

Revisión sobre estudios del uso de microdosificación con alucinógenos que combinan técnicas psicoterapéuticas con administraciones de LSD, MDMA o Psilocibina, como complementos farmacológicos en psicopatologías crónicas, trastornos moderados, altos, graves o crónicos, así como en enfermedades potencialmente mortales

September 1, 2023 Aldo Chiquini

La microdosificación (o las microdosis) hace referencia al ingerir una dosis muy baja de una sustancia psicodélica, donde no hay efectos de alteraciones cognitivas, afectivas, perceptivas y neurofisiológicas. Recientemente instituciones como la MAPS, la Universidad Johns Hopkins, el Imperial College of London y la FDA, a dicha microdosificación le han designado como «terapia innovadora», ya que...